International Clinical Trial: First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (NCT07646353) titled 'First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults' on June 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: GlaxoSmithKline

Condition: Malaria, Falciparum

Intervention: Biological: GSK4425689A SC Biological: GSK4425689A IV

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 12, 2026

Target Sample Size: 40

To know more, visit https://clinicaltri...